Wyoming 2023 Regular Session

Wyoming House Bill HB0119

Introduced
1/16/23  
Report Pass
1/30/23  
Engrossed
2/2/23  
Refer
2/3/23  

Caption

Medical prescriptions-off label purposes.

Impact

If enacted, HB 0119 would significantly modify how medications may be prescribed and dispensed in Wyoming. It allows licensed prescribers such as physicians, physician assistants, and pharmacists to use their professional judgment when it comes to administering treatments that may not be strictly aligned with FDA labeling, thus broadening treatment options available for patients. This could lead to innovative therapies for patients but raises questions regarding the safety and effectiveness of such treatments.

Summary

House Bill 0119 focuses on the ability of healthcare providers in Wyoming to prescribe and dispense medications for off-label use. The bill defines off-label indication as the prescribing of FDA-approved prescription drugs for uses that differ from the indications approved by the FDA. It aims to provide legal immunity for prescribers and pharmacists from disciplinary actions related to these off-label prescriptions, provided that patients give informed consent acknowledging the off-label use.

Sentiment

The sentiment surrounding the bill appears to be mixed. Proponents advocate for increased flexibility in prescribing practices, citing the potential benefits for patients requiring alternative treatments. On the other hand, there are concerns about the lack of oversight and potential for misuse of off-label prescriptions, which could lead to public health risks. The nuanced debate reflects divergent opinions on balancing innovative treatment options against the need for regulatory safeguards.

Contention

Notable points of contention include the ethical implications of off-label prescribing practices and the potential risks associated with a lack of regulatory oversight. Opponents of the bill may argue that without clear guidelines, there is a risk of healthcare providers prescribing medications inappropriately, which could undermine patient safety. Supporters contend that the bill allows for necessary discretion that can tailor patient care more effectively, particularly in cases where standard treatments may not be suitable.

Companion Bills

No companion bills found.

Previously Filed As

WY HB0164

Medical prescriptions-off-label purposes.

WY HB102

Prescriptions; off-label use.

WY SB711

Prescriptions; off-label use.

WY SB041

Prescription Drugs For Off-label Use

WY H3117

Prescriptions

WY SF0151

Wyoming prescription drug transparency act.

WY HB1344

Prescriptions for off-label medications; terms; moral, ethical, or religious exemptions; immunity from liability; good- faith effort; temporary privileges; at-home and outpatient dispensing; disciplinary action; exceptions; World Health Organization; effective date.

WY SF0144

Chloe's law-children gender change prohibition.

WY HB1466

Relative to the off-label use of prescription drugs and relative to pharmacy prescriptions.

WY HB0234

Medical Ethics Defense Act.

Similar Bills

NJ A5782

Establishes deadline for DEP implementation of prescribed burn program, and provides for establishment of prescribed burn acreage goals, schedules, calendars, training program, and mobile deployment units to provide on-site prescribed burn training and assistance.

CA AB2585

Prescribed burns: burn managers: liability.

CA AB2741

Prescription drugs: opioid medications: minors.

CA AB771

Burning of forest lands: forest land owners.

CA AB2091

Fire prevention: prescribed burns: insurance pool.

IN HB1557

Prescribed burning.

AR SB415

To Establish The Arkansas Prescribed Burning Act.

CA AB2086

Controlled substances: CURES database.